Oncology Partnerships T-Cypher Bio is building an oncology pipeline focused on shared tumor-specific TCR targets and rare functionally-defined T cell clones, creating opportunities for co-development or licensing with pharma focused on solid tumors.

Data Licensing The company generates large immune repertoire datasets via high-throughput immune synapse profiling, opening opportunities to license data or provide computational modelling services to accelerate external TCR discovery.

TCR Platform Proprietary platforms that map the intracellular target space and T cell specificity can be licensed or offered as a service to other biotech and pharma parties seeking to advance TCR-based immunotherapies.

UK Market Access Based in Oxford, UK, the business has potential to leverage UK and EU funding programs and to pursue collaborations with academic centers and NHS partners.

Growth Potential With revenue in the 1-10 million range and a focused team, there is strong potential for strategic partnerships with larger biopharma to accelerate scale of the platform and advance the oncology program.